<DOC>
	<DOCNO>NCT00779441</DOCNO>
	<brief_summary>The study compare relative bioavailability ( rate extent absorption ) 10 mg Zolpidem tablets Ohm Laboratories Inc. 10 mg AmbienÂ® tablet distribute Sanofi-Synthelabo , Inc. follow single oral dose ( 1x10 mg tablet ) healthy adult volunteer administer non-fasting condition</brief_summary>
	<brief_title>Bioequivalence Study Zolpidem 10 mg Tablets Under Fed Conditions</brief_title>
	<detailed_description>This single-center , randomize , open label , two-way cross study conduct non-fasting condition . Subjects check clinical facility day prior dose least 10 hour prior dose administration . On study day 1 , subject dose single oral dose ( 1x10mg tablet ) test reference product thirty minute initiation standardize , high fat breakfast precede overnight fast . Following seven day wash period , subject return dosed alternative treatment per randomization Thirty-six ( N=36 ) volunteer enrol study 17 female 19 male . Subject 22 drop study participation prior period II check due adverse event</detailed_description>
	<mesh_term>Zolpidem</mesh_term>
	<criteria>1 . Healthy men woman 18 year age old time dose 2 . Weights within Â±20 % height body frame per Desirable weight adult ( 1983 Metropolitan Height Weight table ) 3 . Volunteers judge investigator healthy base medical medication history , physical examination , electrocardiogram , clinical laboratory result 4 . Volunteers willing participate study sign copy write consent form 5 . If female : Of childbearing potential , practice acceptable method birth control duration study judge b investigator ( ) , condom spermicide , intrauterine device ( IUD ) , abstinence ; Was menopausal least 1year ; Was surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) Subject candidate must enrol study meet follow criterion : 1 . Volunteers recent history drug alcohol addiction abuse 2 . Volunteers presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease ( determined clinical investigator ) 3 . Volunteers clinical laboratory test value outside accept reference range , confirm reexamination , deem clinically significant 4 . Volunteers reactive screen hepatitis B surface antigen , hepatitis C antibody , HIV antibody 5 . Volunteers positive drug abuse screen screen study 6 . Female volunteer demonstrate positive pregnancy screen 7 . Female volunteer currently breast feed 8 . Volunteers history clinically significant allergy include allergy 9 . Volunteers clinically significant illness 4 week prior Period I dose ( determined clinical investigation ) 10 . Volunteers currently use tobacco product 11 . Volunteers take drug know induce metabolism inhibit hepatic metabolism 28 day prior period I dose . 12 . Volunteers report donate great 150 mL blood within 28 day prior period I dose . All subject advise donate plasma four week complete study 13 . Volunteers donate plasma ( e.g . plasmapheresis ) within 14 day prior period I dose . All subject advise donate plasma four week complete study 14 . Volunteers report receive investigational drug within 28 day prior period I dose 15 . Volunteers report take systemic prescription 14 day prior Period I dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Bioequivalence zolpidem 10mg tablet</keyword>
</DOC>